Abivax pares gain after denying AstraZeneca speculation
SeekingAlpha
Momentum traders are flagging several health care stocks that may be overheated heading into the new quarter. As of Feb. 18, 2026, elevated RSI readings suggest recent gains could be vulnerable to pullbacks despite strong headlines.
AstraZeneca has surged roughly 14% over the https://t.co/eVMOTmA1TE
@Benzinga
AstraZeneca profit climbs on cancer and heart drug demand
MarketWatch
Walmart joins Nasdaq 100 on January 20, replacing AstraZeneca
Cryptopolitan
AstraZeneca hails major breakthroughs with breast-cancer drugs
MarketWatch
AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.
MarketWatch
Trump reaches deal with AstraZeneca to lower U.S. drug prices, MSNBC reports
CNBC
AstraZeneca shares leap with FDA set to review drug to treat breast cancer
MarketWatch
*HSBC OVERTAKES ASTRAZENECA AS BRITAIN'S BIGGEST LISTED COMPANY
🇬🇧🇬🇧 https://t.co/KH8CPXfmMr
@Investingcom
China State Administration for Market Regulation approves sale of FibroGen China to AstraZeneca
SeekingAlpha
AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
MarketWatch
AstraZeneca will invest US$50bn in the US to expand manufacturing and research
Forexlive
AstraZeneca shares show signs of life after successful trials of hypertension drug
MarketWatch
FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - CNBC
CNBC
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year. https://t.co/b5hOwTxWaU https://t.co/Wq5EsZGLK5
@Reuters
AstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambition
SeekingAlpha
FibroGen sells China unit to AstraZeneca for $160 million
SeekingAlpha
AstraZeneca's Enhertu breast cancer drug added to China's state insurance list https://t.co/ANXcJ37J86 https://t.co/a5p6npwgWs
@Reuters
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy
CNBC
AstraZeneca $AZN Q3 2024 earnings were released today before the market opened:
- Revenue: $13.56B vs $13.09B
- EPS: $1.04 vs $1.03 https://t.co/L9YMcRERaB
@Benzinga
AstraZeneca says detained China head has lawyer, but company still in dark https://t.co/e0JZ5gcq4d https://t.co/lqYDxOEImo
@Reuters
AstraZeneca sheds £15 billion of market cap as weight-loss-pill data underwhelms investors
MarketWatch
AstraZeneca to pay up to $2 billion to license cardiovascular drug
MarketWatch
Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line https://t.co/xnIivIV4Db https://t.co/myFZAy8W5A
@Reuters
US FDA approves AstraZeneca's non-small cell lung cancer treatment https://t.co/mkQJ7SUj5c https://t.co/d9xgiaNCJh
@Reuters
Why CEO AstraZeneca believes the pharmaceutical company can almost double revenues by 2030
CNBC
AstraZeneca completes acquisition of Fusion Pharmaceuticals
SeekingAlpha
Ontario court approves AstraZeneca/Fusion acquisition plan
SeekingAlpha
Fusion shareholders give green light to AstraZeneca acquisition
SeekingAlpha
AstraZeneca to build $1.5 billion cancer drug manufacturing plant in Singapore - Reuters
Reuters
Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial https://t.co/1HCc8JsuZy https://t.co/bHfQ2WNCOK
@Reuters
AstraZeneca to increase 2024 dividend by 7% on strong growth https://t.co/EwtVdAukKA https://t.co/0HTPRgW6KL
@Reuters
AstraZeneca will buy Fusion Pharmaceuticals for ~$2B
SeekingAlpha
AstraZeneca to expand rare disease pipeline with $1.05B Amolyt Pharma acquisition
SeekingAlpha
Gracell Biotechnologies receives shareholder approval for merger with AstraZeneca
SeekingAlpha
U.S. FDA approves AstraZeneca's Tagrisso-chemo combo https://t.co/KFPYOpWTGR https://t.co/RPuUvz1XQ1
@Reuters
Icosavax ticks lower as HSR filing for AstraZeneca deal withdrawn, refiled
SeekingAlpha
Sell AstraZeneca, says UBS, which upgrades European rivals including GSK
MarketWatch
AstraZeneca to buy Gracell Biotechnologies for $1.2 billion
SeekingAlpha
Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment
MarketWatch
Cytokinetics gains amid report of Novartis, AstraZeneca takeover interest
SeekingAlpha
AstraZeneca to acquire vaccine maker Icosavax in ~$1.1B deal
SeekingAlpha
Icosavax enters agreement to be acquired by Astrazeneca
SeekingAlpha
AstraZeneca partners with AI company to find cure for cancer
CoinTelegraph
AstraZeneca and Absci Collaborate on AI-Driven Cancer Therapy Development
Cryptopolitan
Drug Giant AstraZeneca Launches Evinova to Quicken Clinical Trials
Decrypt
CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage
CNBC
AstraZeneca prioritizes US for RSV drug amid surge in cases https://t.co/2KxUhShyqN https://t.co/mxvzb9oZ2C
@Reuters
AstraZeneca adds player to obesity drug race, but Eli Lilly remains in the lead
CNBC
AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines
MarketWatch
FAQ
Berapa harga saham AstraZeneca PLC hari ini?
Harga saat ini dari AstraZeneca PLC adalah 204.27 USD — harga tersebut telah meningkat sebesar 1.72% dalam 24 jam terakhir. Pantau kinerja harga saham AstraZeneca PLC lebih dekat di grafik lanjutan.
Apa simbol saham AstraZeneca PLC?
Tergantung pada bursa, simbol saham bisa berbeda. Misalnya, di bursa PINK, saham AstraZeneca PLC diperdagangkan dengan simbol AZNCF.
Apakah harga saham AZNCF naik?
Saham AZNCF telah menurun sebesar 0.00% dalam seminggu terakhir, telah meningkat sebesar 5.17% dalam sebulan terakhir, dan telah meningkat sebesar 54.28% dalam setahun terakhir. Lihat lebih banyak data di grafik AZNCF.
Apa rekomendasi analis untuk AZNCF?
Hingga 09 apr 2026, dari 0 rekomendasi analis, mayoritas memberikan rating AZNCF sebagai hold.
Apa kapitalisasi pasar AZNCF?
Hingga hari ini, AZNCF memiliki kapitalisasi pasar sebesar 290.6B USD. Jelajahi daftar saham kami yang diperingkat berdasarkan kapitalisasi pasar untuk membandingkan AZNCF dengan saham lainnya.
Apakah AZNCF merilis laporan keuangan?
Ya, Anda dapat melacak keuangan AZNCF dalam laporan tahunan dan kuartalan di Profit.com.
Kapan tanggal laporan pendapatan AZNCF berikutnya?
AZNCF akan merilis laporan pendapatan berikutnya pada 27 apr 2026. Pantau acara yang akan datang dengan Kalender Pendapatan kami.
Berapa pendapatan AZNCF untuk kuartal terakhir?
AZNCF melaporkan pendapatan sebesar $2.12 per saham untuk kuartal terakhir, lebih tinggi dibandingkan dengan estimasi $2.1 per saham, yang menghasilkan kejutan 0.95%. Estimasi pendapatan untuk kuartal berikutnya adalah $2.59 per saham. Lihat lebih banyak rincian tentang pendapatan AZNCF di Profit.com.
Berapa pendapatan AZNCF untuk kuartal terakhir?
Pendapatan AZNCF untuk kuartal terakhir adalah 15.5B USD, lebih tinggi dibandingkan dengan estimasi 14.77B USD. Estimasi pendapatan untuk kuartal berikutnya adalah 14.64B USD. Lihat lebih banyak statistik di laporan keuangan AZNCF di Profit.com.
Berapa Laba Bersih AZNCF untuk kuartal terakhir?
Pendapatan bersih AZNCF untuk kuartal terakhir adalah 2.33B USD, sementara kuartal sebelumnya menunjukkan 2.53B USD laba bersih yang mencatatkan perubahan -8.17%. Lihat lebih banyak statistik di laporan keuangan AZNCF di Profit.com.
¿AZNCF paga dividendos?
Sí, los dividendos de AZNCF se pagan trimestralmente. El último dividendo por acción fue 3.13. A partir de hoy, el rendimiento por dividendo (TTM)% es 1.70%.
¿Cuántos empleados tiene AZNCF?
A partir de 09 apr 2026, AZNCF emplea aproximadamente a 94300 empleados. Consulta si AZNCF está en nuestra lista de empleadores más grandes.
¿Qué es el EBITDA de AZNCF?
El EBITDA, que mide el rendimiento operativo de una empresa, refleja sus mejoras en eficiencia. El EBITDA de AZNCF es 20.42B USD, con un margen EBITDA actual de 16.17%. Consulta más estadísticas en los rapporti finanziari de AZNCF en Profit.com.
¿Cómo comprar acciones de AZNCF?
Al igual que otras acciones, las acciones de AZNCF se cotizan en bolsas de valores como PINK. La forma más fácil de comprarlas es a través de un bróker de bolsa en línea. Simplemente abre una cuenta, sigue los procedimientos del bróker y comienza a operar. Alternativamente, puedes practicar comerciando acciones de Tesla en Profit.com en torneos Playtrade o elegir un bróker recomendado para operar directamente.
¿Debería invertir en las acciones de AZNCF?
Invertir en acciones requiere una investigación exhaustiva, que incluye analizar las finanzas de la empresa, las noticias relacionadas y el análisis técnico. Actualmente, las recomendaciones de los analistas técnicos de Tesla muestran una calificación de hold.